Current stock page

Financial Data

SLS Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

SLSSELLAS Life Sciences Group, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Strong Relative Position

NeutralEdge 9/10
$7.86−$0.17 (−2.12%)

Latest quote

  • Momentum
    55
  • Value
    —
  • Quality
    73
  • Risk resilience
    32
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$0$0$0$0$0
Gross Profit-$11.31M$0$0$0$0$0$0$0
Operating Income-$11.31M-$10.63M-$9.25M-$8.26M-$7.08M-$6.87M-$6.06M-$6.92M
Net Income-$10.09M-$9.61M-$8.41M-$7.66M-$6.79M-$6.6M-$5.81M-$6.74M
EPS-$0.05-$0.05-$0.05-$0.05-$0.06-$0.07-$0.07-$0.09
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$5.94M-$7.59M-$8.85M-$4.92M-$7.07M-$7.33M-$9.07M-$7.15M
Capital Expenditure$0$0$0$0$0$0$0$0
Free Cash Flow-$5.94M-$7.59M-$8.85M-$4.92M-$7.07M-$7.33M-$9.07M-$7.15M
Net Cash Provided By Operating Activities-$5.94M-$7.59M-$8.85M-$4.92M-$7.07M-$7.33M-$9.07M-$7.15M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$141.09M$145.38M$114.18M$78.35M$51.56M$32.31M$34.96M$19.43M
Total Debt$599K$737K$871K$1M$599K$737K$870K$1M
Cash And Cash Equivalents$134.71M$138.44M$107.2M$71.89M$44.42M$25.3M$28.4M$13.89M
Total Liabilities$9.29M$7.73M$6.77M$7.47M$5.93M$6.16M$7.2M$9.97M
Total Stockholders Equity$131.81M$137.66M$107.41M$70.87M$45.63M$26.15M$27.76M$9.47M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio12.0715.198.3811.233.546.074.46—
P/S ratio————————
Debt To Equity00.010.010.010.010.030.030.11
Free Cash Flow Yield-1.72%-1.36%-3.13%-3.57%-18.96%-19.76%-27.24%—
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio12.0715.198.3811.233.546.074.46—
P/S ratio————————
Return On Equity-27.13%-23.58%-27.42%-37.90%-56.85%-100.42%-97.73%-3.26%
Debt To Equity00.010.010.010.010.030.030.11

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-39.56x
Pb12.07x
EPS Growth Yoy20.13%
Gross Margin0.00%
Operating Margin0.00%
ROE-31.95%
ROIC-29.79%
Debt To Equity0
FCF Yield-1.72%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$7.86
Volume11.17M
RSI (14)34.66
MACD-0.95
MACD signal-0.81
MACD histogram-0.14
ADX (14)25.27
SMA (50)$11.03
SMA (200)$8.78
ATR (14)$0.96
Historical volatility (annualized)114.55%
Volume (20-day average)7.53M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score32/100
Beta2.27
Annual volatility109.89%
Max Drawdown-49.16%
Sharpe Ratio2.04
VaR (95%, 1-day)-8.91%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

SLS Financial Data FAQ

What is SELLAS Life Sciences Group, Inc.'s revenue?

SELLAS Life Sciences Group, Inc.'s revenue is one of the core financial data points for SLS. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is SELLAS Life Sciences Group, Inc.'s revenue growing?

Revenue growth shows whether SELLAS Life Sciences Group, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is SLS's EPS?

SLS's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is SELLAS Life Sciences Group, Inc.'s net income?

SELLAS Life Sciences Group, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does SELLAS Life Sciences Group, Inc. generate?

Free cash flow shows how much cash SELLAS Life Sciences Group, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does SELLAS Life Sciences Group, Inc. have?

Cash and debt help frame SLS's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.